Universal reference book for medicines
Name of the drug: FUSIMET (FUSIMET)

Active substance: dioxomethyltetrahydropyrimidine, fusidic acid

Type: Antibacterial agent for external use

Manufacturer: BIOSINTEZ (Russia)
Composition, form of production and packaging
Ointment for external use
from light yellow to yellow.

100 g

fusidic acid sodium salt 2 g

dioxomethyltetrahydropyrimidine 1 g

Excipients: sodium disulfite, povidone (polyvinylpyrrolidone low molecular weight medical), lanolin anhydrous, petrolatum, purified water.

15 g - aluminum tubes (1) - cardboard packs.

25 grams - tubes of aluminum (1) - packs of cardboard.

150 g - aluminum tubes (1) - packs of cardboard.

15 g - polymer tubes (1) - packs of cardboard.

25 g - polymer tubes (1) - packs of cardboard.

150 g - polymer tubes (1) - packs of cardboard.

0.5 kg - polymer cans (1) - cardboard packs.

0.93 kg - polymer cans (1) - packs of cardboard.

2 kg - polymer cans (1) - packs of cardboard.

3 kg - polymer cans (1) - packs of cardboard.

0.5 kg - cans of glass (1) - packs of cardboard.

0.93 kg - cans of glass (1) - packs of cardboard.

2 kg - cans of glass (1) - packs of cardboard.

3 kg - cans of glass (1) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2014.

PHARMACHOLOGIC EFFECT

Sodium fusidate (fusidin sodium) is the sodium salt of fusidic acid, an antibiotic with a high specific antimicrobial activity against Staphylococcus spp.
(including those resistant to penicillins, streptomycin, chloramphenicol, erythromycin), Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus spp., Moraxella spp. and Corynebacterium spp.
Has a high antimicrobial activity against Staphylococcus epidermidis (methicillin-resistant and mitticillin-sensitive);
less - with respect to Streptococcus spp.(including Streptococcus pneumoniae).
Inactive with Escherichia coli, Salmonella spp., Proteus spp.
and other gram-negative bacteria, as well as protozoa and fungi.
Dioxomethyltetrahydropyrimidine is a stimulator of cellular regeneration, has anabolic and anti-catabolic activity, shortens the healing time for wounds.

PHARMACOKINETICS

Sodium fusidate when applied externally penetrates deeply into the skin in the area of ​​affected areas.

Dioxomethyltetrahydropyrimidine with local application in the form of an ointment is practically not absorbed into the systemic bloodstream.

INDICATIONS

Treatment of purulent-inflammatory skin diseases caused by microorganisms sensitive to fusidate sodium:

- superficial folliculitis;

- furunculosis;

- pyoderma;

- impetigo;

- Hydradenite;

- deep wounds and abrasions;

- sycosis;

- infected wounds and ulcerous surfaces.

Treatment of burns I-III-IV degree as an antimicrobial and regenerating agent in the second phase of the wound process,

DOSING MODE

Outwardly.
After removal of pus and necrotic masses, ointment is applied a thin layer 1-2 times a day, with burns - 2-3 times a week.
The duration of treatment depends on the form and severity of the disease.

With extensive wound processes, it is possible to combine the ointment with the intake of sodium fusidate inside.
In such cases, the dose of sodium fusidate is prescribed by a doctor.
The average duration of therapy with ointment is 10-14 days, it is possible to extend the course to 3 weeks.

SIDE EFFECT

Rarely (> 0.01% and <0.1%): allergic reactions.

Very rarely (<0.01%): a local irritant effect in the form of redness and itching, which usually does not require drug withdrawal.

If any of the side effects indicated in the manual are aggravated, or any other side effects not indicated in the instructions are noted, you should inform the doctor immediately.

CONTRAINDICATIONS

- individual intolerance to the components of the ointment;

- pregnancy, the period of breastfeeding;

- Children under 18 years of age (due to lack of data);

- leukemia (leukemia, especially myeloid), lymphogranulomatosis, hemoblastosis, malignant bone marrow diseases.

PREGNANCY AND LACTATION

Contraindicated use of the drug during pregnancy and during breastfeeding.

OVERDOSE

Over the period of post-marketing use of the drug, no cases of overdose have been observed.

DRUG INTERACTION

There is an increase in the effect of the ointment when combined with the use of ointment and sodium fusidate tablets.

The effect of the ointment increases when combined with antibiotics (semisynthetic penicillins, tetracyclines, macrolides).
The route of administration of an antibiotic is not critical.
TERMS OF RELEASE FROM PHARMACY

Without recipe.

TERMS AND CONDITIONS OF STORAGE

At a temperature not higher than 15 ° С.
Keep out of the reach of children. Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!